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Human immunodeficiency virus (HIV) infection can lead to a variety of clinical cutaneous manifestations. These
cutaneous disorders occur universally during the course of HIV infection. Cutaneous manifestations of HIV are very
diverse. The course and clinical presentation of HIV in individuals who have access to highly active antiretroviral therapy
(HAART) is completely different  from that in those who do not. Many of the HIV cutaneous presentations seen in South
Africa become chronic and progressive. There is a marked reduction in the incidence of opportunistic infections and
neoplasms in North America, Western Europe and Australia, where there is access to HAART. 
Approximately 90% of patients will develop one or more skin diseases during the course of their illness. It is therefore
crucial that health professionals become familiar with and are able to recognise the various skin manifestations of HIV.
Thirty-seven per cent of patients present with skin lesions
as a marker of HIV infection. As the CD4+ lymphocyte cell
count decreases, the severity of the skin condition
increases, multiple skin lesions are seen, and frequent
relapses are encountered. There tends to be increased
severity of infections with known pathogens and
occurrence of infection with unusual and exotic pathogens. 
Patients often present with florid clinical patterns which
fail to respond to conventional therapy. Correlation
between skin disorders with CD4+ lymphocyte count in
patients with HIV/AIDS in an American study is illustrated
in Fig. 1.
The incubation period from the time of exposure to the
development of an acute febrile syndrome is about 2 - 6
weeks. It is estimated that 50 - 70% of patients will have
the acute syndrome after infection, however, of these only
25% have symptoms severe enough to warrant medical
attention. Patients present with an infectious mono-
nucleosis-like picture characterised by fever, sore throat,
ACUTE SEROCONVERSION ILLNESS
Fig. 1. Correlation between mean CD4 cell count and
incidences of specific skin disorders in patients with HIV
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myalgia, malaise, headache and
enlarged cervical lymph nodes.
The cutaneous manifestations may
take the form of a diffuse morbilliform
rash (Fig. 2), a papular exanthem or a
maculopapular rash with central
petechiae, with occasional involve-
ment of the palms of the hands and
soles of the feet.
In one-third of patients the picture
may include an enanthem characteri-
sed by ulcerations, aphthous-like
lesions and candidiasis.
The duration of the acute episode is
about 1 - 2 weeks, and it may be
complicated by hepatitis and neuro-
logical symptoms. 
Cutaneous fungal infections are
common in both HIV-infected and
uninfected individuals. They are the
commonest infectious manifestation
of immunosuppression related to HIV,
ranging from superficial muco-
cutaneous candidiasis to life-
threatening disseminated infections
like histoplasmosis. Fungal infections
occur early in the course of HIV
infection, when they manifest with
oral candidiasis, and later on as AIDS-
defining conditions like histoplas-
mosis and cryptococcosis. A thorough
knowledge of the diagnosis and
treatment of these conditions is
therefore important to decrease the
significant morbidity associated with
cutaneous fungal infections in
HIV/AIDS.
CANDIDIASIS
This is the commonest mucocutaneous
manifestation, affecting 20 - 70% of
individuals with HIV.1 Asymptomatic
colonisation of the oropharynx occurs
in up to 60% of HIV-infected patients.
The incidence of oral candidiasis
increases as the CD4+ count declines,
and it is a marker of rapid HIV
progression. As oral candidiasis is
common in infants under 6 months of
age, other clinical markers of HIV
should be sought in this age group.
However, recurrent and severe oral
candidiasis in the older child (over 6
months of age) is indicative of
immunosuppression. The incidence
has declined with the use of fluco-
nazole prophylaxis for cryptococcal
meningitis.
Candidiasis most often affects the
tongue and buccal mucosa, causing
thick, whitish plaques, but may also
present as angular cheilitis. (Fig. 3).
Less common manifestations are
paronychia (Fig. 4), onychomycosis,
recurrent vaginal and urethral
involvement and cutaneous involve-
ment, predominantly of the flexures.
Children may present with candidiasis
in the napkin area and other flexures
(axillae and neck folds) and chronic
paronychia with nail dystrophy. Severe
oral involvement with dysphagia
indicates oesophageal candidiasis.
Disseminated candidiasis, although
rare, is often fatal and should be
considered in ill patients with fever
and severe immunosuppression.
Therapy is aimed at clearance and
prevention of dissemination. Good
oral hygiene is important, together
with the use of topical azoles in the
form of pastilles, troches or lozenges
twice daily for 14 days. For refractory
cases or where oesophageal involve-
ment is suspected, oral azoles are
indicated: itraconazole 200 mg daily
for 5 days or fluconazole 100 mg daily
for 5 days. The therapeutic dose in
children is 3 - 6 mg/kg. Higher doses
and longer duration of treatment may
be necessary for recurrent episodes in
severely immunosuppressed individu-
als. Cutaneous candidiasis may regress
on HAART alone, in the absence of
specific antifungal agents.
DERMATOPHYTOSIS
Dermatophytosis involving the skin,
hair and nails is a common
opportunistic infection in patients
with HIV/AIDS. Although the frequen-
cy is not necessarily increased in these
individuals, they are prone to more
extensive and atypical forms which
may be resistant to therapy. The
commonest pathogen causing tinea
infections is Trichophyton rubrum.
Tinea corporis, pedis and capitis (Figs
5, 6 and 7) may present as typical
‘ringworm’ infection with active edges
and central clearing, or present in
atypical forms (extensive scaling, lack
of an active edge, interdigital tinea
pedis spreading to the dorsa of the
feet, and ‘two feet, one hand’
syndrome with bilateral tinea manum
and pedis). Folliculitis on hair-bearing
areas may be complicated by
Majocchi's granulomas and deep
abscesses.
Certain types of onychomycosis (Fig.
8) are prevalent in HIV infection.
Proximal white superficial onycho-
mycosis and peri-ungual involvement
are the commonest, and tend to
spread to involve multiple fingers and
toes as the CD4+ count declines.
FUNGAL INFECTIONS
Fig. 3. Oral candidiasis.
Fig. 4. Chronic paronychia.
In children, HIV can present with
painful tinea capitis, e.g. kerion, and
may progress to scarring alopecia.
Since the diagnosis of superficial
fungal infections may be difficult,
confirmation with potassium hydro-
xide (KOH) microscopy is essential to
exclude other pathologies. Therapy is
important, as fungal infections are
persistent and may act as a portal of
entry for secondary staphylococcal
and streptococcal infections.
Dermatophyte infections in HIV-
infected adults and children are ideally
treated with oral antifungals. The
choice of antifungal agent depends on
other concomitant therapies, as drug
interactions are significant. Therapy
may be required for longer than
normal and HIV-infected patients are
prone to relapse.
Tinea corporis is treated with either
griseofulvin 500 mg - 1 g daily for 28
days, itraconazole 200 mg/day for 7
days or  terbinafine 250 mg/d for 14
days.
Onychomycosis is more resistant to
therapy and treatment needs to be of
longer duration. Terbinafine 250 mg/d
should be given for 3 months for
fingernail infections and for 4 months
for toenail infections, and itraconazole
in a pulsed dosage of 400 mg/d for 1
week per month  is necessary for 3
months for fingernail infections and
for 4 months for toenail infections.
Itraconazole should be taken with
fatty food or an acidic drink to
enhance absorption and also to
combat the hypochlorhydria or
achlorhydria to which HIV-infected
individuals are susceptible.  Itrocona-
zole is a p450 enzyme inhibitor, so the
prescribing physician needs to be
aware of the danger of co-admini-
stration of other drugs metabolised by
this enzyme system, e.g. protease
inhibitors (PIs). In very ill patients with
onychomycosis on multiple drugs it is
best simply to keep the nails short 
and resort to topical therapy, e.g.
amorolfine nail lacquer.
Primary and secondary prophylaxis is
important to prevent relapse and re-
infection. This may be achieved by
benzoyl peroxide washes of the feet,
drying carefully between the web
spaces, and application of an
antifungal cream or powder.
The first line of therapy for tinea
capitis in children is micronised
griseofulvin at 10 - 15 mg/kg for 6 - 8
weeks.  Shorter duration of therapy
can be achieved with itraconazole (5
mg/kg/d for 28 days) and terbinafine
(250 mg > 40 kg, 125 mg 20 - 40 kg
and 62.5 mg < 20 kg for 28 days).
Compliance is best with shorter
duration of therapy.
Patients on HAART will experience less
frequent infections, which could clear
without specific antifungal therapy.  If
treated with antifungals they will




sis and cryptococcosis are AIDS-
defining conditions as they occur with
profound immunodeficiency. Skin
lesions signify dissemination via the
bloodstream, the primary infection
being in the lungs.
Cryptococcosis
This is a common systemic mycosis
due to the yeast Cryptococcus
neoformans. Skin involvement occurs
in 10% of patients with systemic
disease. The lesions are polymorphous
and may present as papules, nodules,
pustules or ulcers (Fig. 9).
The site most commonly affected is
the head and neck, although lesions
may be widespread. They may be
confused with molluscum contagio-
sum, so biopsy is important to make a
definitive diagnosis. Cryptococcosis is
a life-threatening condition if
untreated. Treatment involves  intra-
venous injections of amphotericin B
for 2 weeks followed by lifelong
maintenance therapy with fluconazole
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Fig. 7. Tinea capitis.
Fig. 8. Onychomycosis.
Fig. 9. Cryptococcus — umbilicated
lesions resembling molluscum
contagiosum.
Fig. 5. Tinea corporis.
Fig. 6. Tinea pedis.
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200 mg daily. Patients on HAART may
present with headache due to im-
mune reconstitution of cryptococcal
meningitis.
Histoplasmosis
Cutaneous histoplasmosis is asso-
ciated with advanced immunosup-
pression, usually at a CD4+ lym-
phocyte count of < 75 cells/µl.
Patients are usually ill, with fever,
anaemia, respiratory symptoms, lym-
phadenopathy, hepatosplenomegaly
and skin lesions. Histoplasmosis is
therefore often misdiagnosed as
tuberculosis, and patients are started
on empiric anti-TB therapy, without
response.
Skin involvement occurs in 5 - 10% of
patients (Figs 10 and 11), and mucosal
involvement is characteristic with
gingival ulcers, plaques, nodules and
abscesses. Owing to the polymor-
phous presentation, a high index of
suspicion is required and biopsy and
culture of lesions is mandatory. In the
absence of skin lesions, blood and
bone marrow culture are sensitive
methodologies. Therapy in the acute
stage is amphotericin B 15 mg/kg by
intravenous injection or itraconazole
400 mg daily for 8 weeks. Lifelong
maintenance therapy should be given,
with itraconazole 200 mg/d or fluco-
nazole 200 mg/d.
Sporotrichosis
Sporotrichosis is caused by the
organism Sporothrix schenckii and can
be classified as lymphocutaneous,
fixed cutaneous, disseminated cuta-
neous or systemic. In HIV/AIDS, skin
lesions may consist of widespread
ulcers, papules, nodules and plaques,
often with systemic involvement (Fig.
12). Local cutaneous infection is more
likely to disseminate. Biopsy and
culture is important to make a
diagnosis, and therapy with itraco-
nazole is effective.
Other systemic mycoses that may
occur but are rare in South Africa are
blastomycosis, penicilliosis and cocci-
dioidomycosis. Accurate diagnosis can
only be made utilising pathological
and mycological investigations. As
more patients are being treated with
HAART, the incidence of systemic
fungal infections will decline.
The most common bacterial infections
in HIV-infected patients are due to
Staphylococcus aureus and Staphylo-
coccus epidermidis. These are common
in the general population, but in HIV-
infected individuals may be more
widespread, recurrent and resistant 
to therapy. S. aureus is the most
common cutaneous and systemic
bacterial pathogen in adults. HIV-
infected patients have increased
Staphylococcus carriage in their nares.
Infection presents with folliculitis,
impetigo, ecthyma and cellulitis. In
addition to S. aureus, Gram-negative
infections such as  ecthyma gangre-
nosum caused by Pseudomonas occur. 
FOLLICULITIS
This common bacterial infection
presents with acneiform papules and
pustules, which may be excoriated.
The common causative organisms 
are S. aureus, S. epidermidis and
P. aeruginosa.
IMPETIGO
These lesions begin as macules that
progress to vesicles and pustules,
which then rupture leaving honey-
coloured crusts. They are particular
common in the perioral and perinasal
areas.  The causative organism is S.
aureus, which is a common cause of
cutaneous infection in the general
population. In HIV infections, however,
lesions may be seen more commonly
in the intertriginous areas. 
SOFT-TISSUE INFECTION
This presents as a warm, red and
tender swelling which may progress to
necrotising fasciitis.
Therapy for a first episode is the
empiric use of antibiotics that will
treat staphylococcal and streptococcal
infections, and taking a specimen for a
Gram stain. Deeper and recurrent
infection warrants samples for
microscopy and culture. If the patient
is severely ill, admission for intra-
venous antibiotic therapy should be
considered and longer duration of
therapy may be required. If the
infection is recurrent, therapy of
staphylococcal carriage with mupi-
rocin may be effective.
Fig. 10. Disseminated histoplasmosis —
facial lesions.
Fig. 11. Disseminated histoplasmosis.
Fig. 12. Linear sporotrichosis.
BACTERIAL INFECTIONS
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BACILLARY ANGIOMATOSIS
This rare condition caused by the spirocheate Rochalimea
henselae presents with angiomatous papules, nodules and
abscesses (Fig. 13).  It occurs in patients with severe
immunosuppression and may be clinically confused with
Kaposi's sarcoma.  Systemic involvement may occur with
pulmonary, hepatic, bone and central nervous system
symptoms.  Histology is important as it is a fastidious
organism and hence difficult to culture. Patients respond
well to erythromycin 500 mg 6-hourly or doxycycline 100
mg twice a day until the lesion resolves.  If the condition is
recurrent, secondary prophylaxis is necessary. Alternative
drugs are the cephalosporins and quinolones.
SYPHILIS
In HIV disease, syphilis progresses more rapidly through all
of the stages.  Syphilis may present atypically or be
refractory to therapy, and laboratory investigations may be
difficult to interpret owing to unusual serological
responses. The primary chancre may consist of multiple
lesions and may be extensive. Secondary syphilis presents
as in the immunocompetent patient, with scaly plaques on
the trunk, muzzle area of the face, palms and soles (Figs 14
and 15). However, it may mimic any other cutaneous
disease and hence a high index of suspicion is required for
diagnosis. Progression to neurosyphilis occurs more rapidly
even if the patient has had optimal treatment. Lues
maligna, an unusual form of secondary syphilis with ulcers,
has been described. False-positive VDRL and RPR tests and
delayed titre responses occur more commonly in HIV-
infected patients. Treatment for primary, secondary and
early latent syphilis is one dose of 2.4 million units of
benzathine penicillin G, and for late latent syphilis or
syphilis of unknown duration 2.4 million units of penicillin
G weekly for 3 weeks. 
MYCOBACTERIAL DISEASE
Tuberculosis
HIV-infected adults are susceptible to tuberculosis and
therefore at increased risk of presenting with cutaneous
hypersensitivity reactions.
Papulonecrotic tuberculid can present with papules and
pustules which ulcerate, usually involving the acral sites
(earlobes, elbows, knees, extensors and buttocks) (Figs 16
and 17).
Lichen scrofulosorum presents as grouped papules on the
trunk (Fig. 18) in patients with underlying lymphadeno-
pathic and bone tuberculosis.
Erythema induratum/nodosum causes ulcers and painful
nodules on the lower limbs, with a bluish edge (Fig.19).
Diagnosis of any of the above hypersensitivity reactions to
tuberculosis is supported by a strongly positive Mantoux
test, histology and investigation for underlying
tuberculosis.  Treatment with standard antituberculosis
therapy for 6 months is effective.
Fig. 13. Bacillary angiomatosis.
Fig. 14. Secondary syphilis, face and palms.
Fig. 15. Secondary syphilis with typical palmar lesions.
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Atypical mycobacteria
Mycobacterium avium, haemophilum and bovis may cause
skin lesions with systemic mycobacterial disease in 10% of
HIV-positive individuals. These infections are associated
with advanced immunosuppression and are uncommon,
partly because of the widespread use of antituberculosis
therapy.  Cutaneous lesions can present as papules,
pustules, abscesses and ulcers. Lesions may present as
nodules involving ascending lymph nodes of a limb.  Biopsy
and culture is essential for an accurate diagnosis, and
therapy with clarithromycin and rifampicin is effective.
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Hill, 1999: 2138-2150.Fig. 18. Lichen scrofulosorum with blistering mantoux.
Fig. 19. Erythema nodosum, lower limbs.
Fig. 17. Papulonecrotic tuberculid with classic earlobe lesions.
Fig. 16. Papulonecrotic tuberculid.
